SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Economic Moat Analysis (2026)
Overall Score
Scale Market Position
Market cap is about $1.74B, which is still small and limits scale advantages.
Revenue per share is $2.83, indicating a modest commercial footprint.
Profitability Returns
Gross margin remains very high at 97.5%, but operating margin is -77.1% and net margin is -87.6%, showing the business is far from durable profitability.
ROIC is -32.1% and ROE is -372.9%, indicating capital is not currently earning attractive returns.
Balance Sheet Resilience
Current ratio is 6.77 and cash ratio is 3.38, so near-term liquidity is strong.
Debt remains heavy relative to capital, with debt-to-capital at 97.5% and financial leverage at 46.6x.
Cash Generation Efficiency
Operating cash flow is negative and free cash flow is negative, so the company is not self-funding from operations.
Cash conversion remains weak, with a cash conversion cycle of 1,722.9 days and inventory turnover of just 0.19x.
Moat Indicators
The company shows no clear evidence of pricing power or durable moat despite a very high gross margin.
Heavy R&D spend at 103.9% of revenue suggests innovation investment, but it has not yet translated into sustained operating leverage.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Syndax Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

